Opioid REMS Hearing Features Top-Level FDA Team – But No Manufacturers

FDA’s most recent public meeting to explore better approaches to managing prescription opioids marked the public debut of its new Opioid Steering Committee. The issue has top management attention at FDA – but the hearing didn’t include any industry speakers.